Higher Numbers of Blood CD14+ Cells before Starting Conditioning Regimen Correlate with Greater Risk of Acute Graft-versus-Host Disease in Allogeneic Stem Cell Transplantation from Related Donors  by Arpinati, Mario et al.
H
C
A
C
I
p
p
r
e
p
e
p
r
c
i
(
c
a
Biology of Blood and Marrow Transplantation 13:228-234 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1302-0001$32.00/0
doi:10.1016/j.bbmt.2006.10.004
2igher Numbers of Blood CD14 Cells before Starting
onditioning Regimen Correlate with Greater Risk of
cute Graft-versus-Host Disease in Allogeneic Stem
ell Transplantation from Related Donors
Mario Arpinati,1 Gabriella Chirumbolo,1 Yogen Saunthararajah,2 Marta Stanzani,1 Francesca Bonifazi,1
Giuseppe Bandini,1 Michele Baccarani,1 Damiano Rondelli2
1Institute of Hematology and Medical Oncology “L & A Seragnoli,” University of Bologna, Bologna, Italy and
2Section of Hematology/Oncology, University of Illinois at Chicago, Chicago, Illinois
Correspondence and reprint requests: Dr. Mario Arpinati, Instituto di Ematologia e Oncologia Medica “L & A
Seragnoli,” Universitá di Bologna, Policlinico S Orsola-Malpighi, Via Massarenti, 9 40138 Bologna, Italy
(e-mail: arpinati@med.unibo.it).
ABSTRACT
Host antigen-presenting cells (APCs) have been shown to induce acute graft-versus-host disease (aGVHD) in
experimental models. In this study, we investigated whether pretransplantation blood levels of host APCs, such
as plasmacytoid and myeloid dendritic cells and monocytes, correlate with the development of aGVHD. A total
of 89 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) from
HLA-matched related (n  48) or unrelated (n  41) donors were enrolled in the study. Blood samples were
analyzed by flow cytometry before initiating the conditioning regimen. In related donor transplants, patient–
donor sex mismatch and monocyte levels significantly correlated with aGVHD grade II–IV in both univariate
and multivariate analyses. Similar results were not observed in recipients of matched unrelated transplants,
possibly due to use of antithymocyte globulin (ATG) or differences in graft source in these patients. In
conclusion, pretransplantation recipient monocyte levels are relevant to the development of GVHD in HSCT
from related donors.
© 2007 American Society for Blood and Marrow Transplantation
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fNTRODUCTION
Dendritic cells (DCs), the most powerful antigen-
resenting cells (APCs), comprise myeloid (mDC) and
lasmacytoid (pDC) subsets [1]. mDCs reside in pe-
ipheral tissues and migrate to T-cell areas of periph-
ral lymphoid organs on maturation [2], whereas
DCs reside in secondary lymphoid organs. Periph-
ral blood (PB) contains low numbers of mDCs and
DCs [3]; nevertheless, it has been shown that mDCs
esiding in peripheral tissues can originate from cir-
ulating CD14 monocytes [4], particularly during
nfection and inﬂammation.
In allogeneic hematopoietic stem cell transplantation
HSCT), acute graft-versus-host disease (aGVHD) is
aused by donor mature T cells targeting host tissues on
lloantigen recognition [5,6]. Host alloantigens can be t
28irectly presented to donor lymphocytes by host
PCs (direct presentation), or can be captured by
onor APCs and then presented to donor T cells
indirect presentation). In experimental models of ma-
or or minor histocompatibility antigen-mismatched
llogeneic HSCT, direct presentation has been dem-
nstrated to be essential in the development of
GVHD [7-9]. Despite previous studies that have cor-
elated levels of circulating DCs and GVHD [10-12],
hether circulating APCs contribute directly to the
ctivation of donor T cells after transplantation has
ot yet been demonstrated in humans. In particular,
he signiﬁcance of different levels of circulating APCs
efore the conditioning regimen is not understood. In
act, myeloablative or reduced-intensity pretransplan-
ation conditioning regimens cause a decline in PB
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Pretransplantation CD14 Cells Correlate with aGVHD 229ell numbers, including DCs [13]. However, after pre-
arative chemoradiotherapy, some of the circulating
PCs may also migrate to peripheral tissues [14] due
o elevated levels of proinﬂammatory cytokines, such
s tumor necrosis factor (TNF)-, or pathogen-de-
ived products, such as lipopolysaccharides [15].
In this study, we tested whether the number of
PCs, such as myeloid and plasmacytoid DCs, or
D14 monocytes measured in the PB of patients
efore initiating the conditioning regimen for an al-
ogeneic HSCT could predict the development of
GVHD. Our ﬁndings show that the level of circulat-
ng monocytes correlates with aGVHD in a multivar-
ate analysis.
ATIENTS AND METHODS
atients
Between January 2002 and December 2004, 89
onsecutive adult patients (31 with acute myelogenous
eukemia [AML]/myelodysplastic syndrome [MDS],
3 with acute lymphocytic leukemia [ALL], 15 with
hronic myelogenous leukemia [CML], 15 with mul-
iple myeloma [MM], and 15 with non-Hodgkin lym-
homa [NHL]/Hodgkin disease [HD]) undergoing
llogeneic HSCT at the University of Bologna were
nrolled in this study after informed consent was ob-
ained. Of these 89 patients, 48 received transplants
rom HLA-matched related donors (47 peripheral
lood stem cell [PBSC], 1 bone marrow [BM]), and 41
eceived transplants from unrelated donors (3 PBSC,
8 BM). A total of 71 patients received myeloablative
egimens, including high-dose busulfan-based (16 mg/
g, n  39), total body irradiation (TBI)-based (800
Gy, n 27), and melphalan-based (140 mg/sm, n 5),
s described previously [10]. In 18 patients, reduced-
ntensity regimens were used, including ﬂudarabine
20 mg/m2, cyclophosphamide 60 mg/kg, and thio-
epa 10 mg/kg (n  10); ﬂudarabine 60 mg/m2 and
elphalan 140 mg/m2 (n  6); and cyclophophamide
00 mg/kg and thiotepa 10 mg/kg (n 2). In 39 of the
1 patients receiving unrelated transplants and 5 of
he 48 receiving related transplants, rabbit-ATG (Fre-
enius-Kabi, Graz, Austria; 15 mg/kg total dose) was
dded to the conditioning regimen from day 5
o 1. GVHD prophylaxis included standard cyclo-
porine and methotrexate in 82 patients and cyclo-
porine and mofetil mycophenolate in 7 patients.
GVHD and chronic GVHD (cGVHD) were graded
ccording to standard criteria.
low Cytometry
Blood samples were obtained from each patient 1
ay before initiating the conditioning regimen and
ere tested by cytoﬂuorimetric analysis. Only samples
ontaining 1 109 white blood cells (WBCs)/L (ie, *7 out of 89) were suitable for analysis. The following
onoclonal antibodies were used, all from Becton Dick-
nson (Mountain View, CA): ﬂuorescein isothiocyanate–
onjugated antilineage (lin) (a mixture of anti-CD3,
CD14, -CD16, -CD19, -CD20, and -CD56), anti-
D34, and anti-CD45; phycoerythrin-conjugated anti-
D11c, anti-CD123, and anti-CD14; and peridin chlo-
ophyll protein –conjugated anti–HLA-DR. mDCs
ere identiﬁed as linCD34CD11cHLA-DR and
DCs as linCD34CD123HLA-DR, as described
reviously [10]. Monocytes were identiﬁed as CD45bright
D14bright in a standard leukogate analysis. Sample ac-
uisition and analysis were performed on a FACSCali-
ur analyzer (BD Biosciences, San Jose, CA) using Cell
uest software. Absolute numbers were deﬁned by mul-
iplying percentages by the WBC count.
tatistical Analysis
The Wilcoxon rank-sum test was used to compare
re-DC numbers in transplant recipients and healthy
ontrols (Figure 1), as well as to compare pre-DC
umbers in patients with distinct gender. The
ruskal-Wallis test was used to compare pre-DC
umbers in patients with different diseases. To corre-
ate pre-DC numbers and patient age, disease dura-
ion, and number of previous treatments, a linear
egression analysis was performed and Pearson’s cor-
elation coefﬁcient was determined. Analysis of vari-
igure 1. PB APC counts in allogeneic HSCT patients and healthy
ontrols. PB mDC, pDC, and monocyte counts, as indicated, were
etermined in patients undergoing allogeneic HSCT before the
tart of pretransplantation chemoradiotherapy (n  82 for mDCs
nd pDCs; n  88 for monocytes) (white boxes) and in healthy
ge-matched controls (n  27) (gray boxes), as described in Mate-
ials and Methods. Horizontal lines indicate median cell counts in
ach group. Boxes indicate interquartile ranges. *P .05; **P .01;
**P  .001 as determined by Wilcoxon’s rank-sum test.
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M. Arpinati et al.230nce (SAS version 8.0 [SAS Institute, Cary, NC]) was
sed to examine the association between aGVHD and
he variables listed in Table 1. GVHD was divided
nto 2 categories: grade 0–I and grade II–IV. The
reconditioning variables of CD14 monocyte num-
ers, mDCs, pDCs, total WBCs, and mDC:pDC ratio
ad a skewed distribution; therefore, statistical analy-
is was performed on ranked counts. Patients were
nalyzed in 2 separate groups, those receiving
atched related donor transplants (n 48) and those
eceiving matched unrelated donor transplants (n 
1). Only variables associated with GVHD (P  .1) in
nivariate analysis were entered into multivariate
nalysis. The comparison of monocyte numbers in
atients with distinct GVHD grades (Figure 2A) was
able 1. Risk Factors for aGVHD in Related and Unrelated Donor Tr
aGVHD grade (n)
Related
(n  44)*
0-1 2-4
(n  29) (n  15)
ecipient age, years (range)§ 42 (36-49) 52 (39-54)
onor
Age§ 39 (32-49) 46 (38-53)
Female into male 4 (14%) 7 (47%)
ource
PBSC 28 (97%) 15 (100%)
BM 1 (3%) 0 (0%)
isease
AML/ALL 11 (38%) 5 (33%)
CML 7 (24%) 0
MM 5 (17%) 5 (33%)
NHL/HD/CLL 6 (21%) 5 (33%)
Aadvanced¶ 20 (69%) 12 (80%)
Disease duration§ 10 (9-24) 28 (13-55)
onditioning
RIC 7 (24%) 6 (40%)
TBI 7 (24%) 3 (20%)
ATG 4 (14%) 0 (0%)
raft §
TNC** 765 (543-985) 848 (755-116
CD34** 4.1 (3.5-5.6) 5.2 (4.8-5.7)
CD3** 182 (153-248) 170 (154-253
ecipient PB§
WBCs†† 5.1 (3.8-6.1) 5 (4.4-5.6)
DC‡‡ 9.6 (4.5-13.8) 8.6 (6.7-14.1
DC‡‡ 3.6 (2.2-5.4) 2.6 (1.2-5.4)
D14 pre-DC‡‡ 238 (207-322) 380 (292-507
atio mDC:pDC 1.8 (1.3-4.4) 5.2 (1.8-7.5)
bbreviations: CLL, chronic lymphocytic leukemia; RIC, reduced-
Six patients (4 related and 2 unrelated) were not evaluable due to
Univariate analysis (P values as determined by analysis of variance
Multivariate analysis (P values as determined by ANOVA as descr
Median values are indicated (interquartile ranges in parentheses);
performed on ranked counts.
Advanced disease was deﬁned as AML and ALL beyond ﬁrst CR,
stage.
Expressed in months.
*Values are expressed as 106cells/kg recipient’s body weight.
†Values are expressed as 103cells/L.
‡Values are expressed as cells/L.one using the Kruskal-Wallis test. Curves comparing cGVHD and cGVHD, overall survival, and relapse
ate depending on pre-DC counts were plotted ac-
ording to the Kaplan and Meier method and analyzed
ccording to the log-rank test.
ESULTS
Absolute numbers of circulating DCs and
onocytes were initially compared in 89 patients
efore allogeneic HSCT and in 27 normal controls
omparable in terms of age and sex. The patients
chedule for HSCT had lower mDC counts (8.8 
06/L [interquartile range, 5.1–14.7  106/L] vs 15.5 
0(e)6/L [12.1–25.1  10(e)6/L]; P  .0006) and pDC
tations
Unrelated
(n  39)
P† P‡
0-1 2-4
P† P‡(n  31) (n  8)
NS 33 (26-44) 36 (25-44) NS
NS 35 (22-56) 27 (20-45) NS
.01 .04 2 (6%) 2 (25%) NS
3 (10%) 0 (0%)
NS 28 (90%) 8 (100%) NS
19 (61%) 5 (63%)
5 (16%) 2 (25%)
4 (13%) 1 (13%)
3 (10%) 0
NS 19 (61%) 7 (87%) NS
NS 17 (11-26) 11 (7-27) NS
NS 5 (16%) 1 (12%) NS
NS 13 (42%) 3 (38%) NS
NS 30 (97%) 8 (100%) NS
NS 300 (225-379) 250 (202-338) NS
NS 2.2 (1.5-3) 1.6 (1.2-3) NS
NS 25 (18-27) 26 (20-28) NS
NS NS 4.4 (3.3-7.2) 4.9 (3.2-7.6) NS
NS NS 8.1 (5.1-19.1) 9.1 (3.8-11.7) NS
NS NS 3.1 (1.5-5.9) 1 (0.4-3.5) NS
.004 .001 323 (189-463) 211 (146-497) NS
NS NS 3.1 (1.5-5.9) 1 (0.4-3.5) NS
ty conditioning; TNC, total nucleated cells; NS, not signiﬁcant.
efore engraftment.
VA] as described in Materials and Methods).
Materials and Methods).
absolute counts had a skewed distribution, statistical analysis was
not in chronic phase, and NHL, HD, CLL, and MM at whateveransplan
0)
)
)
)
intensi
death b
[ANO
ibed in
because
CMLounts (3.3  106/L [1.4–5.5  106/L] vs 8.6  106/L
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Pretransplantation CD14 Cells Correlate with aGVHD 2315.8–13.1  106/L]; P  .00001), but higher monocyte
ounts (308/L [204–450 /L) vs 177/L [116–377/
L]; P  .04) (Figure 1). Nevertheless, the pretrans-
lantation mDC:pDC ratio was signiﬁcantly higher in
atients than in controls (3.3 [1.7–5.7] vs 1.7 [1.3–2.6];
 .0005), due to much lower levels of pDCs than
DCs in the patients compared with normal controls
Figure 1). Blood mDC and monocyte counts did not
orrelate with age, sex, disease type, disease duration,
r the number of previous treatments (not shown).
nstead, pDC counts were lower in patients who had
igure 2. Correlation between recipient PB monocyte counts befor
ation from HLA-identical related donors. A, Evaluable patients we
0; grade 2, n  7; grade 3, n  6; grade 4, n  3). Circles indicate
anges. P  .01 as determined by the Kruskal-Wallis test. B–E, Pati
ounts (C), or monocyte counts (D, E) higher or lower than the m
VHD (B–D) or cGVHD (E) GVHD was determined using the
urves, as determined by the log-rank test, is indicated.eceived more previous treatments (P  .005) or ste- goid-containing treatments (P  .002), and in those
ith MM (P  .01).
aGVHD grade II–IV was observed in 15 patients
ho received related transplants and in 8 patients who
eceived unrelated transplants. Six patients (4 in the
elated donor group and 2 in the unrelated donor
roup) died before engraftment and could not be
valuated for aGVHD. Because factors potentially af-
ecting aGVHD, including stem cell source, graft
omposition, and ATG use, were unevenly distributed
n the related and unrelated transplant groups, the 2
plantation and increased aGVHD after allogeneic HSC transplan-
siﬁed depending on aGVHD grade (grade 0, n  19; grade 1, n 
n monocyte counts in each group. Error bars indicate interquartile
re classiﬁed according to whether they had pDC counts (B), mDC
value, as determined on the whole patient population. Time to a
-Meier method. The signiﬁcance of the differences between thee trans
re clas
media
ents we
edian
Kaplanroups were analyzed separately (Table 1).
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M. Arpinati et al.232In the related transplant group, univariate analysis
ound an association among aGVHD grade II–IV, the
resence of sex-mismatched (female into male) do-
ors, and pretransplantation monocyte levels (Table
). Other potential risk factors for aGVHD, including
onor and recipient age, disease type, and status, con-
itioning regimen, GVHD prophylaxis, and graft
omposition, did not correlate with aGVHD. In mul-
ivariate analysis, both sex mismatch (female into
ale) and monocyte levels were associated with
GVHD grade II–IV (Table 1). When early death was
ombined with acute GVHD to exclude its role as a
ompeting factor, a correlation between both factors
nd the composite end point of death and aGVHD
as still seen (P  .04 and .003, respectively; data not
hown).
Comparable median numbers of monocytes were
bserved in patients with aGVHD grade I and in
hose with no GVHD (224/L [interquartile range,
09–286/L] vs 238/L [193–393/L], whereas
onocyte counts were higher in patients with grade II
308/L [271–464/L]), grade III (382/L [374–
98/L]), and grade IV (431 [406–1962]) aGVHD
P  .01) (Figure 2A). After dividing the patients into
groups according to the median number of mono-
ytes, mDCs, or pDCs observed in the study, we
ound that patients with a monocyte count greater
han the median value (308/L) had a higher inci-
ence (52%) of aGVHD than the others (23%)
P  .01) (Figure 2D). However, the risk of
GVHD was not related to pDC (Figure 2B) or
DC counts (Figure 2C).
Among patients receiving transplants from family
onors, 35 patients (73%) were alive in CR after a
edian follow-up of 309 days (range, 28–1460 days).
mong the 34 patients that could be evaluated ( 100
ays follow-up), 17 developed cGVHD, including 7
35%) in the low-monocyte group and 10 (63%) in the
igh-monocyte group. A trend toward a higher actu-
rial probability of chronic GVHD was observed in
atients with higher monocyte counts (Figure 2E).
elapse rate was similar in patients with higher and
ower monocyte counts (11% vs 12%, respectively).
owever, due to disease heterogeneity and short fol-
ow up, the lack of relationship between monocyte
ounts and relapse cannot be considered conclusive.
In transplants from unrelated donors with ATG
dded to the conditioning regimen, none of the cell
ypes analyzed correlated with aGVHD grade II–IV,
GVHD, overall survival, or relapse rate (data not
hown).
ISCUSSION
In this study, we have shown that patients with
igher levels of CD14 circulating cells before initi- ption of a conditioning regimen for allogeneic HSCT
rom a related donor are more likely to develop
GVHD grade II–IV. Although aGVHD often has
een associated with the cellular composition of the
raft, our data suggest for the ﬁrst time in a clinical
etting a correlation between blood APCs in the re-
ipient and the risk of developing aGVHD after allo-
eneic HSCT. However, of the various types of APCs
nalyzed, CD14 cells correlated with a greater inci-
ence of aGVHD but circulating mDCs and pDCs
id not, as was also reported previously [11]. A possi-
le explanation for this ﬁnding is that PB contains
ore monocytes than DCs, and these monocytes are
apable of migrating to lymphoid organs or tissues
nd rapidly differentiating into DCs on release of
ytokines in inﬂammatory sites.
The relevance of recipient APCs in the induction
f aGVHD has been previously demonstrated in ani-
al models of GVHD [3-6]. Nevertheless, the mech-
nism through which higher recipient monocyte
ounts predispose to aGVHD remains unclear and
ay not depend solely on antigen presentation. In
urine studies, circulating host monocytes are re-
ruited to tissues after pretransplantation chemoradio-
herapy through CCR2–CCL2 interactions [16,17].
his may be one reason, together with direct toxicity,
hy we found an association between pretransplanta-
ion chemoradiotherapy and a rapid reduction of PB
onocyte numbers. In fact, 90% of our patients had
100 monocytes per L on the day of transplanta-
ion (data not shown).
In humans, aGVHD is known to be associated
ith a more rapid recovery of monocytes producing
nterleukin-12 and TNF- [18,19]. However, in this
tudy, posttransplantation recovery of monocytes,
DCs, and pDCs at 1 and 3 months did not correlate
ith pretransplantation numbers of circulating mono-
ytes (data not shown). Moreover, monocyte recovery
id not correlate with aGVHD, as also described pre-
iously [10]. These data are in agreement with the
reviously reported observation that 100% circulating
endritic cells and monocytes are of donor origin as
arly as 7 days posttransplantation [20]. However,
hese data do not exclude a correlation between pre-
ransplantation circulating monocyte numbers and
PC numbers in peripheral tissues and lymphoid or-
ans early after transplantation. Thus our hypothesis
s that the number of circulating monocytes of the
ecipient detected before initiation of the condition-
ng regimen might predict the amount of myeloid
PCs that will be found in peripheral tissues and/or
ymphoid organs after transplantation. Experiments
esigned to test this hypothesis in humans will need to
ake into consideration multiple variables, such as the
egree of HLA compatibility, type of conditioning
egimen, and the immunosuppressive therapy used to
revent aGVHD, which may affect the kinetics of
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Pretransplantation CD14 Cells Correlate with aGVHD 233ctivation, migration, and maturation of monocytes
nd of T cells.
The lack of correlation between monocyte levels
nd aGVHD in persons receiving unrelated trans-
lants can be partially explained by the use of thymo-
lobulin, which potentially depletes graft T cells as
ell as recipient APCs [21]. Interestingly, patients
eceiving ATG before transplantation had a trend
oward lower monocyte counts on the day of trans-
lantation (data not shown). Alternatively, the differ-
nce between related and unrelated transplants in our
tudy may possibly be related to the type of graft (BM
n unrelated donors vs PBSC in related donors) used
n these settings. In fact, the lower T-cell dose in BM
ompared with PBSC could potentially reduce mono-
yte migration and activation [17]. In addition, T cells
rom granulocyte colony- stimulating factor–mobi-
ized PBSC grafts are less sensitive to B7-dependent
ostimulation [22] and may be selectively committed
o Th2 polarization [23].
Although larger studies addressing the role of mono-
ytes in transplant are warranted, our initial observation
f a correlation between recipient PB monocyte levels
efore transplant and the risk of aGVHD after trans-
lantation suggest a possible role of host accessory cells
n aGVHD in human allogeneic HSCT as well. These
esults may further support the hypothesis, previously
emonstrated in mice experiments [7], that depletion of
ost APCs before transplantation may prevent aGVHD.
o address this hypothesis, we will test whether new
rugs such as thymoglobulin, alemtuzumab [13], and
ortezomib [24] at doses speciﬁcally targeting mono-
ytes and DCs may be useful in experimental designs
imed at preventing or decreasing the incidence of se-
ere aGVHD.
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